Compare Ascendis Pharma A/S (ASND) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs SoundHound AI Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while SoundHound AI Inc trades at $6.6 (market cap $2.89B). The key difference: Ascendis Pharma A/S is far larger — about 6.1× SoundHound AI Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals.
| ASND | SOUN | |
|---|---|---|
Market Cap | $17.74B | $2.89B |
Sector | Health | Technology |
52-Week High | $277.18 | $21.40 |
52-Week Low | $163.32 | $5.90 |
Enterprise Value | $18.11B | $2.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SOUN trades at $6.64, down 0.6% on the day, with a bearish technical signal driven by moving averages. The company shows strong revenue growth but significant losses, with a net income margin of -91.84% in 2026. Recent news highlights expansion in voice AI and the planned LivePerson acquisition, yet investor caution persists due to cash burn and execution risks. Analyst consensus remains bullish with a $13.00 price target, but the stock faces pressure from high valuation multiples and negative profitability metrics.
The outlook for SOUN hinges on scaling its AI platform to achieve profitability, supported by enterprise adoption and strategic deals. Investment opportunity lies in its growth trajectory and market position in voice AI, but risks include sustained losses, competitive pressures, and reliance on financing. Investors should weigh the high upside potential against substantial operational and financial risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
